NVS Jan 2025 60.000 call
| Previous close | 42.50 |
| Open | 42.50 |
| Bid | 41.50 |
| Ask | 45.80 |
| Strike | 60.00 |
| Expiry date | 2025-01-17 |
| Day's range | 42.50 - 42.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Novartis raises full-year guidance on Q1 beat, drug sales
Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
GlobeNewswireNovartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra
Investor's Business DailyHow Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint
Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.
